Monopar Therapeutics Inc.
MNPR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $83,380 | $24,669 | $150,708 | $200,176 |
| - Cash | $45,816 | $7,266 | $8,186 | $20,304 |
| + Debt | $0 | $0 | $8 | $0 |
| Enterprise Value | $37,564 | $17,403 | $142,531 | $179,872 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$16,162 | -$8,831 | -$10,537 | -$9,127 |
| % Margin | – | – | – | – |
| Net Income | -$15,586 | -$8,402 | -$10,516 | -$9,103 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.36 | -0.58 | -0.83 | -0.73 |
| % Growth | -134.5% | 30.1% | -13.7% | – |
| Operating Cash Flow | -$6,404 | -$7,858 | -$7,229 | -$7,317 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$6,404 | -$7,858 | -$7,229 | -$7,317 |